

Grifols' Alternative Performance Measures (APM)

Definitions and Uses

Alternative Performance Measures Q3 2025

Introduction

On October 5, 2015, the European Securities and Markets Authority (ESMA) published Guidelines 2015/1415 on Alternative Performance Measures (APMs), which are mandatory for all issuers whose securities are admitted to trading on an official market and who must publish regulated information by Directive 2004/109/EC on transparency, to improve the comparability, reliability, and understandability of these measures.

These Guidelines apply to any regulated information such as management reports accompanying annual accounts or interim financial statements, interim management statements, results presentations disclosed as a material fact, etc.

Grifols' financial statements are prepared in accordance with EU-IFRS and other provisions of the applicable financial reporting framework and include APMs prepared in accordance with the group's financial reporting model, as defined in the guidelines issued by ESMA.

APMs are used by Grifols' management to evaluate the group's financial performance, cash flows, and financial position in making operational and strategic decisions for the group. Therefore, they are useful information for investors and other stakeholders.

APMs are prepared on a consistent basis for the periods presented in this document. They should be considered in addition to IFRS measurements, may differ from definitions given by regulatory bodies relevant to the group and to similarly titled measures presented by other companies. They have not been audited, reviewed, or verified by the external auditor of the Grifols group. Rounding may explain any slight differences in the reconciliations.

All the figures presented in this document pertain to Grifols combined, including the combined data from Grifols and Biotest. The only exception is the figures reported on a standalone basis of the most relevant entities in which Grifols has non-controlling interests.

1) “Reported EBITDA (P&L)”

Definition

EBITDA, or “Earnings Before Interest, Taxes, Depreciation, and Amortization,” is a financial indicator which determines the operating margin of a company prior to deducting interest, taxes, impairment, restructuring costs, and amortization. This is constructed as EBIT excluding depreciation of property, plant, and equipment, depreciation of right-of-use assets, amortization of intangible assets, and impairment of property, plant, and equipment, right-of-use assets, and intangible assets as well as restructuring costs.

This is defined as the combination of Grifols and Biotest EBITDA figures for any given period.

Relevance of Use

Since it does not include financial and tax indicators or accounting expenses not involving cash outflow, it is used by management to evaluate the company's results and profitability over time, making comparisons with peers within the sector more straightforward. This metric illustrates how the company's operating profitability changes yearly, excluding non-cash items. Management periodically utilizes this metric to establish financial forecasts. Moreover, it's facilitating comparisons across companies, industries, and regions.

It provides a valuable of the company's performance and profitability over time, as well as that of other comparable companies.

Reconciliation

<i>In thousand of euros</i>	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
OPERATING RESULT (EBIT)	354,202	348,854	268,857	371,859	317,034
<i>Depreciation & Amortization</i>	(102,848)	(107,035)	(111,750)	(110,130)	(108,364)
Reported EBITDA	457,050	455,889	380,607	481,990	425,398
<i>% Net revenue</i>	24.5%	24.1%	21.3%	24.4%	23.7%

Last Twelve Months (LTM)

Definition

This is defined as EBITDA related to the last 12 months of the business cycle.

Relevance of Use

We may sometimes use LTM Consolidated Reported EBITDA as this financial metric assesses a company's profitability over the past twelve months. It builds upon the concept of EBITDA by focusing on a specific timeframe. Management uses such a measure to compare different periods using the same standardized measure.

2) "Adjusted EBITDA"

Definition

This is defined as consolidated EBITDA on a profit and loss basis plus: (i) extraordinary, unusual, or non-recurring charges and expenses; (ii) any other non-recurring costs of doing business; minus (iii) non-recurring revenues and earnings.

Relevance of Use

It provides a valuable measure for period-to-period business comparisons, excluding the effect of non-cash expenses and non-recurring items not indicative of Grifols' ongoing operating performance, including restructuring and transaction costs. Such measure helps the management to have a clearer picture of the performance of the core business of the company during a specific period.

Reconciliation

In thousand of euros

	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q3 2025 LTM	Q3 2024 LTM
OPERATING RESULT (EBIT)	354,202	348,854	268,857	371,859	317,034		
<i>Depreciation & Amortization</i>	(102,848)	(107,035)	(111,750)	(110,130)	(108,364)		
Reported EBITDA	457,050	455,889	380,607	481,990	425,398		
<i>% Net revenue</i>	<i>24.5%</i>	<i>24.1%</i>	<i>21.3%</i>	<i>24.4%</i>	<i>23.7%</i>		
Cash							
Restructuring costs and Others	8,056	9,873	1,817	3,044	22,918	22,789	57,268
Transaction costs	6,888	3,842	7,466	9,306	7,882	27,502	58,934
Biotest Next Level Project	10,051	5,481	6,738	7,340	5,113	29,610	59,934
Total Cash Adjustments	24,995	19,195	16,021	19,689	35,913	79,901	176,136
Non-cash							
Impairments	-	-	3,850	24,265	787	28,115	2,581
Total Non-Cash Adjustments	-	-	3,850	24,265	787	28,115	2,581
Total adjustments	24,995	19,195	19,872	43,954	36,700		
Adjusted EBITDA	482,045	475,084	400,479	525,944	462,098		
<i>% Net revenue</i>	<i>25.8%</i>	<i>25.1%</i>	<i>22.4%</i>	<i>26.6%</i>	<i>25.8%</i>		

Last Twelve Months (LTM)

Definition

This is defined as EBITDA related to the last 12 months of the business cycle.

Relevance of Use

We may sometimes use LTM Consolidated Adjusted EBITDA as this financial metric assesses a company's profitability over the past twelve months. It builds upon the concept of EBITDA by focusing on a specific timeframe. Management uses such a measure to compare different periods using the same standardized measure.

3) "EBITDA reported attributable to Non-Controlling Interest (NCI)"

Definition

Consolidated EBITDA according to profit and loss of the most relevant entities in which Grifols has non-controlling interests.

Relevance of Use

It provides a valuable measure for period-to-period comparisons of the business's profitability of each Non-Controlling Interest (NCI) based on the reporting requirements. This measure assesses the NCI performance and profitability over time and includes all the specific details of the entities in which Grifols has non-controlling interests.

Reconciliation

In thousand of euros	LTM Q3 2025			
	GDS	Biotest	BPC	Haema
Profit after tax from continuing operations	130,929	(116,831)	44,895	6,332
Income tax expense	(34,544)	28,844	(12,598)	(9,033)
Financial result	78,728	(34,433)	(2,242)	6,919
Amortisation and depreciation	(45,761)	(50,871)	(7,433)	(8,556)
Consolidated EBITDA	132,507	(60,370)	67,168	17,003
% of non-controlling interest	45%	20%	100%	100%

4) "Operating Working Capital"

Definition

Working capital (WC) is defined as the sum of the balance sheet items i) "inventories" and ii) "trade receivables," less "trade payables".

Relevance of Use

This Working capital analysis is a valuable tool for the company management to make informed strategic decisions such as optimizing inventory management, ability to manage short term finances, fund growth and repay debt. Additionally, it provides a good understanding of the group operational activities and it's financial situation.

5) "Free Cash Flow pre mergers and acquisitions (M&A)"

Definition

This is defined as the FCF pre M&A generated by the company calculated as EBITDA Adjusted- Net Working Capital - CAPEX (including capitalized IT and R&D, and extraordinary growth CAPEX) - Others - Interest - Taxes. In the Consolidated Annual Accounts, this reconciles to Cash flow generation from operating and investing activities excluding impact from M&A and associated costs and expenses. Excludes lease payments, consistent with prior disclosed guidance

Relevance of Use

Management considers this measure critical for understanding Grifols' ability to generate available cash, excluding mergers and acquisitions costs and other associated cost and expenses. This provides a better understanding of the company's ability to generate cash in the upcoming years, as such non-recurring events are not expected to occur again.

Reconciliation

In million Euros

	Q3'25	Q3'24	2025 YTD	2024 YTD
EBITDA Adjusted	482	462	1,358	1,253
Changes in working capital	(38)	(23)	(196)	(198)
CAPEX	(70)	(166)	(282)	(388)
R&D and IT	(37)	(33)	(109)	(96)
Taxes	(52)	(32)	(99)	(95)
Interests	(55)	(55)	(345)	(395)
Others	(29)	(26)	(138)	(150)
Free Cash Flow pre M&A	203	127	188	(69)

Note: CAPEX for includes the previously referred as "Extraordinary growth CAPEX" and Others include the previously referred as "Restructuring and transaction costs"

"Net financial debt Reported"

Definition

This is defined as the amount by which Grifols' and relevant entities with NCI, total financial liabilities exceed its total financial assets, including cash and cash equivalents. It includes the impact of IFRS 16, which specifies how an IFRS reporter will recognize, measure, present, and disclose leases.

Relevance of Use

"Net financial debt" is the main APM used by management to measure the Grifols' indebtedness over time. The financial community broadly employs this metric to evaluate leverage and facilitate comparisons over time with other peers.

Reconciliation

<i>In millions of euros except ratio.</i>	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Non-Current Financial Liabilities	9,093	9,118	9,390	9,491	8,836
Current Financial Liabilities	595	522	657	676	1,017
Cash and Cash Equivalents	(621)	(559)	(753)	(980)	(645)
Net Financial Debt	9,067	9,081	9,294	9,187	9,208

6) "Net Financial Debt Reported Attributable to Non-Controlling Interest (NCI)"

Definition

This is defined as the amount by which Grifols's relevant entities with NCI, total financial liabilities exceed its total financial assets, including cash and cash equivalents. It includes the impact of IFRS 16, which specifies how an IFRS reporter will recognize, measure, present, and disclose leases.

Relevance of Use

It provides a valuable measure for period-to-period comparisons of indebtedness of each Non-Controlling Interest (NCI) based on the reporting requirements.

Reconciliation

<i>In thousand of euros</i>	LTM Q3 2025			
	GDS	Biotest	BPC	Haema
Cash and cash equivalents	(1,818)	(65,748)	(6,974)	(30,474)
Financial assets/liabilities with Grifols	(1,083,916)	664,291	-	-
Leasing liabilities (leases of real estate of plasma donation centres)	11,031	57,874	50,962	20,829
Loans and other financial liabilities	1,597	72,624	-	-
Total Balance Sheet Net Debt	(1,073,107)	729,040	43,988	(9,644)

7) "Leverage Ratio Reported"

Definition

This ratio is calculated as "Net financial debt as per Balance Sheet" divided by "EBITDA" generated in the same comparable period.

Relevance of Use

This ratio is used by management to assess indebtedness over time and examine the financial structure and degree of debt to capital contributed by shareholders and financing entities. Leverage is the primary measure used to evaluate and compare the Company's financial position in different periods and concerning its peers.

Reconciliation

<i>In millions of euros except ratio.</i>	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Non- Current Financial Liabilities	9,093	9,118	9,390	9,491	8,836
Current Financial Liabilities	595	522	657	676	1,017
Cash and Cash Equivalents	(621)	(559)	(753)	(980)	(645)
Net Financial Debt	9,067	9,081	9,294	9,187	9,208

<i>In millions of euros except ratio.</i>	LTM Q3'25	LTM Q2'25	LTM Q1'25	LTM Q4'24	LTM Q3'24
OPERATING RESULT (EBIT)	1,344	1,307	1,257	1,192	1,075
<i>Depreciation & Amortization</i>	(432)	(437)	(445)	(439)	(443)
Reported EBITDA	1,776	1,744	1,702	1,631	1,518

Leverage Ratio Reported	5.1x	5.2x	5.5x	5.6x	6.1x
--------------------------------	-------------	-------------	-------------	-------------	-------------

8) "Liquidity"

Definition

This is defined as the sum of Cash and cash equivalents, on-demand cash deposits at financial institutions and short and long-term credit facilities that remain undrawn at the end of the period.

Relevance of Use

Liquidity denotes a company's capacity to cover all cash requirements for the day-to-day operation of the business and to settle its short-term obligations, those due within a year. These indicators offer management insight into the business's short-term financial well-being.

9) Others

"Non-recurring items"

Definition

These expenses, which do not arise from ordinary business, are not regular. They may be incurred in more than one period, but they do not have continuity over time. They occur at a point in time or are related to a specific event, and it's important to understand this concept clearly.

More specifically, "Restructuring cost" relates primarily to restructuring activities, such as implementing the Operational Improvement Plan, which began in the first half of 2023. "Transaction Cost" relates mainly to the expenses associated with the external services and advisories that the company receives in the recent M&A and financing transactions that the company has performed. "One-Offs" relate primarily to exceptional events that are not directly part of the company's ongoing business and operations and that are not expected to be repeated.

Relevance of Use

The main performance measures employed by management, Such as EBITDA and Free Cash Flow, exclude nonrecurring items of this kind, which arise at a point in time or relate to a specific event not associated with the operations of the company and that will not repeat periodically.

"Operational Expenditures (Opex)"

Definition

Opex refers to the total operating expenses incurred in running the business. It includes "selling, general & Administrative expenses" plus "research and development expenses."

Relevance of Use

Management uses Opex to examine trends in fixed and variable recurring operating expenses involved in running the business from one year to the next and the percentage changes relative to sales. This helps analyze operating leverage and profitability.

“Constant Currency (cc)”

Definition

Constant currency is a technique used to eliminate the effects of fluctuations in foreign exchange rates when comparing a company's financial performance over a specific period.

Relevance of Use

This provides management with valuable insights into a company's underlying business performance by excluding exchange rate fluctuations over a specific period.

“Like for Like (LFL)”

Definition

Like-for-like figures are adjusted to account for the impact of the IRA Part D Redesign and the Fee-for-Service /GPO reclassification. In Q1'2025, these fees are now accounted for in our Gross-to-Net Sales rather than in Opex.

Relevance of Use

This provides management with valuable insights into a company's underlying business performance by excluding the impacts over a specific period, allowing for comparison with periods where such impacts did not occur.

On an additional note, the company undertakes to disclose the consolidated EBITDA ratios according to profit and loss (APM), adjusted EBITDA (APM), and net financial debt (APM). Hence, investors have all the information available.

It is important to note that we will continue to report the debt-to-equity ratio under the Credit Agreement in the appendices to our quarterly earnings presentations and other financial publications. This ratio, which is a key component of our financial reporting, is not considered an APM as it is not intended to reflect the business's financial performance. Instead, it serves as a benchmark for the company's financial leverage ratio under the Credit Agreement.

10) “Adjusted EBITDA as per Credit Agreement” (non-APM)

Definition

This is defined as net income on a consolidated basis for the Group, plus (i) all financial results, (ii) any losses on ordinary course hedging obligations, (iii) any foreign currency translation, transaction or exchange losses, (iv) any loss of any equity-accounted investee, (v) tax expense, (vi) depreciation, (vii) amortization, write-offs, write-downs, and other non-cash charges, losses and expenses, (viii) impairment of intangibles, (ix) non-recurring losses, (x) transactions costs, (xi) extraordinary, unusual, or non-recurring charges and expenses including transition, restructuring and “carveout” expenses, (xii) any costs and expenses relating to the Issuer’s potential or actual issuance of Equity Interests and (xiii) the amount of cost savings, adjustments, operating expense reductions, operating improvements and synergies, in each case on a “run rate” basis and in connection with acquisitions, investments, restructurings, business optimization projects and other operational changes and initiatives; less (i) interest income, (ii) non-recurring gains, (iii) any income or gains on ordinary course hedging obligations (iv) foreign currency translation, transaction or exchange gains and (v) any income of any equity-accounted investee, in each case, for the last 12 months.

Relevance of Use

It provides a useful measure for period-to-period comparisons of profitability of the business, as it is related to the reporting requirement of the Credit Agreement. This is a critical calculation requirement per the credit agreement, showing Grifols’ profitability levels. This measure is used by Grifols’ lenders in accordance with adhering to covenant conditions.

Reconciliation

<i>In millions of euros except ratio.</i>	LTM Q3'25	LTM Q2'25	LTM Q1'25	LTM Q4'24	LTM Q3'24
OPERATING RESULT (EBIT)	1,344	1,307	1,257	1,192	1,075
<i>Depreciation & Amortization</i>	(432)	(437)	(445)	(439)	(443)
Reported EBITDA	1,776	1,744	1,702	1,631	1,518
IFRS 16	(117)	(118)	(117)	(113)	(113)
Restructuring costs, impairments and others	51	67	68	65	76
Transaction costs	28	28	41	49	59
Cost savings, operating improvements and synergies on a “run rate”	174	173	165	159	146
Share of profits assoc core activit 2024	4	9	(39)	(38)	(81)
Total adjustments	139	159	119	122	87
Adjusted EBITDA LTM as per Credit Agreement	1,915	1,903	1,820	1,753	1,605

11) "Net financial debt as per the Credit Agreement" (non-APM)

Definition

This is the definition stated in Grifols's Credit Agreement and it is defined as the amount by which Grifols's total financial liabilities exceed its total financial assets, including cash and cash equivalents. It excludes the impact of IFRS 16, which specifies how an IFRS reporter will recognize, measure, present and disclose leases.

Relevance of Use

This is a critical calculation requirement per the credit agreement, showing Grifols' net financial debt levels. This measure is used by Grifols' lenders in accordance with adhering to covenant conditions. This is also a key metric used for Leverage Ratio as per the Credit Agreement.

Reconciliation

<i>In millions of euros except ratio.</i>	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Non-Current Financial Liabilities	9,093	9,118	9,390	9,491	8,836
Non-recurrent Lease Liabilities (IFRS16)	(966)	(978)	(1,026)	(1,025)	(969)
Current Financial Liabilities	595	522	657	676	1,017
Recurrent Lease Liabilities (IFRS16)	(111)	(112)	(119)	(117)	(111)
Cash and Cash Equivalents	(621)	(559)	(753)	(980)	(645)
Net Financial Debt as per Credit Agreement	7,990	7,992	8,149	8,046	8,128

12) "Leverage Ratio per Credit Agreement" (non-APM)

Definition

This ratio is calculated as "Net financial debt as per Credit Agreement" divided by "Adjusted EBITDA as per the Credit Agreement".

Relevance of Use

This is a critical calculation requirement per the credit agreement, showing Grifols' debt to EBITDA levels. This measure is used by Grifols' lenders in accordance with adhering to covenant conditions.

Reconciliation

<i>In millions of euros except ratio.</i>	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Non-Current Financial Liabilities	9,093	9,118	9,390	9,491	8,836
Non-recurrent Lease Liabilities (IFRS16)	(966)	(978)	(1,026)	(1,025)	(969)
Current Financial Liabilities	595	522	657	676	1,017
Recurrent Lease Liabilities (IFRS16)	(111)	(112)	(119)	(117)	(111)
Cash and Cash Equivalents	(621)	(559)	(753)	(980)	(645)
Net Financial Debt as per Credit Agreement	7,990	7,992	8,149	8,046	8,128

<i>In millions of euros except ratio.</i>	LTM Q3'25	LTM Q2'25	LTM Q1'25	LTM Q4'24	LTM Q3'24
OPERATING RESULT (EBIT)	1,344	1,307	1,257	1,192	1,075
<i>Depreciation & Amortization</i>	(432)	(437)	(445)	(439)	(443)
Reported EBITDA	1,776	1,744	1,702	1,631	1,518
IFRS 16	(117)	(118)	(117)	(113)	(113)
Restructuring costs, impairments and others	51	67	68	65	76
Transaction costs	28	28	41	49	59
Cost savings, operating improvements and synergies on a "run rate"	174	173	165	159	146
Share of profits assoc core activit 2024	4	9	(39)	(38)	(81)
Total adjustments	139	159	119	122	87
Adjusted EBITDA LTM as per Credit Agreement	1,915	1,903	1,820	1,753	1,605

Leverage Ratio as per Credit Agreement	4.2x	4.2x	4.5x	4.6x	5.1x
---	-------------	-------------	-------------	-------------	-------------

13) "Leverage Ratio per Credit Agreement Attributable to NCI" (non-APM)

Definition

This ratio is calculated as "Net financial debt as per Credit Agreement" divided by "Adjusted EBITDA as per the Credit Agreement".

Relevance of Use

This is a critical calculation requirement per the credit agreement, showing Grifols's relevant entities with NCI debt to EBITDA levels. This measure is used in accordance with adhering to covenant conditions.

Reconciliation

	LTM Q3 2025			
	GDS	Biotest	BPC	Haema
<i>In thousand of euros</i>				
Profit after tax from continuing operations	130,929	(116,831)	44,895	6,332
Income tax expense	(34,544)	28,844	(12,598)	(9,033)
Financial result	78,728	(34,433)	(2,242)	6,919
Amortisation and depreciation	(45,761)	(50,871)	(7,433)	(8,556)
Consolidated EBITDA	132,507	(60,370)	67,168	17,003
Impact IFRS16- Finance Leases (leases of plasma donation centre properties)	(2,503)	(8,395)	(5,759)	(4,762)
Restructuring costs	629	2,650	148	230
Impairments	-	19,154	-	-
Share of profits assoc core activit	-	4,388	-	-
Consolidated EBITDA under Credit Agreement	130,633	(42,574)	61,557	12,471
% of non-controlling interest	45%	20%	100%	100%
Consolidated EBITDA according to Credit Agreement non-controlling interest	58,785	(8,344)	61,557	12,471
Cash and cash equivalents	(1,818)	(65,748)	(6,974)	(30,474)
Financial assets/liabilities with Grifols	(1,083,916)	664,291	-	-
Leasing liabilities (leases of real estate of plasma donation centres)	11,031	57,874	50,962	20,829
Loans and other financial liabilities	1,597	72,624	-	-
Total Balance Sheet Net Debt	(1,073,107)	729,040	43,988	(9,644)
Impact IFRS16- Finance Leases (leases of plasma donation centre properties)	(11,031)	(57,874)	(50,962)	(20,829)
Total Net Financial Debt according to Credit Agreement	(1,084,137)	671,166	(6,974)	(30,474)
Total Net Financial Debt according to Credit Agreement non-controlling interest	(487,862)	131,546	(6,974)	(30,474)